3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Glioma
3
Wilms Tumor
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Neuroepithelial
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Hodgkin Disease
1
Gliosarcoma
1
Glioblastoma
1
Ependymoma
1
Diffuse Intrinsic Pontine Glioma
1
Desmoplastic Small Round Cell Tumor
1
Interventions
Filgrastim
9
X-Rays
7
Phantoms, Imaging
7
Specimen Handling
6
Magnetic Resonance Spectroscopy
6
Granulocyte Colony-Stimulating Factor
6
Temozolomide
5
Nuclear Medicine Department, Hospital
5
Melphalan
5
Cyclophosphamide
5
Busulfan
5
Stem Cell Transplantation
4
Carboplatin
4
Biopsy
4
Topotecan
3
Thiotepa
3
Radiotherapy
3
Peripheral Blood Stem Cell Transplantation
3
Itraconazole
3
Ifosfamide
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
sargramostim
2
palbociclib
2
olaparib
2
liposomal amphotericin B
2
larotrectinib
2
ixabepilone
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Wilms Tumor
×
CLR1404
×
CNS
×
Clear all
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled